November 2025 in “Journal of Diabetes Investigation” In this case study, a man with Werner syndrome and diabetes saw improved glycemic control and insulin resistance with dapagliflozin, suggesting its potential usefulness for managing diabetes in similar patients.
April 2026 in “Research Square” This study found that dapagliflozin enhanced mitochondrial quality control and adaptive autophagy in human cardiomyocytes under hypoxic stress, suggesting that these mechanisms may contribute to the cardioprotective effects of sodium-glucose cotransporter 2 inhibitors in ischemic injury.
2 citations
,
January 2025 in “touchREVIEWS in Endocrinology” This study suggests that sodium-glucose cotransporter-2 inhibitors, alone or with metformin or GLP1RA, may improve metabolic and hormonal parameters in women with polycystic ovary syndrome.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.
4 citations
,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.